Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HSD17B3 | P37058 | 5/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4851937 | 0.85 | KDM4E (0.41) | MEN1KMT2ASMYD3L3MBTL1LMNA | |
| SCHEMBL1827517 | 0.83 | PDE4B (0.46) | MEN1KMT2ASMYD3L3MBTL1TDP1 | |
| SCHEMBL4190166 | 0.82 | MEN1 (0.37) | MEN1KMT2ASMYD3L3MBTL1LMNA | |
| SCHEMBL13062695 | 0.80 | MEN1 (0.47) | MEN1KMT2ASMYD3L3MBTL1LMNA | |
| SCHEMBL6763737 | 0.80 | MAPT (0.50) | MEN1KMT2ASMYD3L3MBTL1MAPT | |
| SCHEMBL8543066 | 0.80 | KDM4E (0.44) | MEN1KMT2ASMYD3L3MBTL1LMNA | |
| SCHEMBL6766834 | 0.76 | MAPT (0.46) | MEN1KMT2ASMYD3LMNAMAPT | |
| SCHEMBL4194809 | 0.76 | ALDH1A1 (0.58) | MEN1KMT2ASMYD3L3MBTL1LMNA | |
| SCHEMBL6112937 | 0.76 | PTPN1 (0.47) | MEN1KMT2ASMYD3LMNAMAPT | |
| SCHEMBL4208102 | 0.75 | MEN1 (0.40) | MEN1KMT2ASMYD3L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2319838-A1 | Therapeutic Molecules and Methods-1 | Cortical Pty Ltd (AU) | 2011-05-11 | — | — | EP | disclosed |
| US-20100323999-A1 | Therapeutic Molecules and Methods-1 | MORAND ERIC FRANCIS | 2010-12-23 | — | — | US | disclosed |
| US-7709514-B2 | Therapeutic molecules and methods-1 | CORTICAL PTY LTD (AU) | 2010-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100323999-A1 | Therapeutic Molecules and Methods-1 | MIF, IL1B, IL1A | MEN1 585/4885KMT2A 4517/4885SMYD3 4345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.